Athersys, Inc. (NASDAQ:ATHX)
| CAPS Rating |
|
|---|---|
| Open | $1.89 |
| Previous Close | $1.88 |
| Daily Range | $1.85 - $1.89 |
| 52-Week Range | $1.00 - $3.10 |
| Market Cap | $43.48M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 49,936 |
| Average Daily Volume | 0 |
ATHX
VS S&P 500 (SPY)
How do you think ATHX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ATHX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ATHX News and Commentary
- Registration Effectiveness Orders Issued By The SEC – SmartMoney
- Comverge To Sell $10 Million Of Stock To Aspire Capital – SmartMoney
- Which Companies Said 'No' to Washington Gridlock? – Minyanville
- Athersys More Threatened Than Most by Falling Share Price – The Motley Fool
- Stem-Cell Stocks May Now Be Worth The Risk – SmartMoney
- Athersys: Grossly Undervalued Given Its Potential – SeekingAlpha
- 4 Biotech Companies That Could Be Buyout Targets – SeekingAlpha
- Insider Buying: 5 Stocks With Significant CEO Purchases – SeekingAlpha
- UPDATE: Athersys, Pfizer Move Stem-Cell Therapy To Mid-Stage – SmartMoney
- Athersys, Pfizer Move Stem-Cell Therapy To Mid-Stage Trial – SmartMoney
- Acorda Hopes to Meet Huge Need in Challenging Stroke Market – SeekingAlpha
- Battle Royale: Pharma Style – Blog at The Motley Fool
- Athersys' Treatment for Transplant Attacks Enters Clinical Trials – Fox Business
- Stem Cell Competition Heating Up – SeekingAlpha
- UPDATE 1-Athersys says granted US patents for stem cell therapy – Reuters
- UPDATE 1-Athersys inks deal with Pfizer on stem-cell therapy – Reuters
RSS Headlines
Fool UK
